PMID: 8844300Jun 1, 1996

Adenosine mediates the antiarrhythmic effect of ischemic preconditioning in isolated rat hearts

Japanese Circulation Journal
Y MiyatakeH Hayakawa

Abstract

Adenosine appears to mediate the preconditioning-induced reduction in infarct size in rabbits and dogs, but little is known about the role of adenosine in preconditioning-induced protection against ischemia-induced arrhythmias. We compared the effects of preconditioning induced by 2 cycles of 5 min of global ischemia and 2 cycles of 5 min of perfusion with either adenosine (100 mumol/L) or the adenosine A1-selective agonist 2-chloro-N6-cyclopentyladenosine (CCPA, 100 nmol/L) in protecting against ischemia-induced arrhythmias in Langendorff-perfused rat hearts. Preconditioning reduced the incidence of ventricular tachycardia (VT) from 100 to 58% and the incidence of sustained VT or ventricular fibrillation (VF) from 92 to 33%. Perfusion with adenosine reduced the incidence of VT from 100 to 55%, the incidence of VF from 67 to 9% and the incidence of sustained VT or VF from 92 to 9%. CCPA reduced the incidence of sustained VT or VF from 92 to 25%. These interventions provided a true reduction in the severity of arrhythmias, rather than merely a delay in the onset. Our results suggest that the stimulation of A1 receptor by adenosine is involved in triggering ischemic preconditioning-induced protection against ischemia-induced arrh...Continue Reading

References

May 1, 1992·Cardiovascular Research·A VeghJ R Parratt
Oct 1, 1992·Journal of Molecular and Cellular Cardiology·A C Cave, D J Hearse
Oct 1, 1992·Cardiovascular Research·D M YellonW B Pugsley
Apr 1, 1992·Journal of Molecular and Cellular Cardiology·Y KusamaM Avkiran
Jan 1, 1995·Circulation Research·M B MitchellA Banerjee
Jul 31, 1993·Lancet·D M YellonW B Pugsley
Mar 1, 1993·Journal of Molecular and Cellular Cardiology·J D ThorntonJ M Downey

Citations

Nov 26, 2010·Biochimica Et Biophysica Acta·John P HeadrickLuke J Haseler
May 27, 2006·Coronary Artery Disease·Harun EvrengulAsuman Kaftan
May 19, 2012·Expert Opinion on Pharmacotherapy·Vikram SharmaD M Yellon

Related Concepts

Adenocard
Cardiac Depressants
Cardiac Arrhythmia
Canis familiaris
Perfusion
Myocardial Reperfusion Injury
Myocardial Ischemia
Rats, Wistar
Purinergic P1 Receptor Agonists

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.